NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Forecast & News

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Tuesday, November, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.09. The firm earned $21.20 million during the quarter, compared to analyst estimates of $20.23 million. Oxford Immunotec Global had a return on equity of 15.77% and a net margin of 199.21%. The company's revenue was up 31.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) earnings per share. View Oxford Immunotec Global's Earnings History.

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Oxford Immunotec Global.

Oxford Immunotec Global will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 equities research analysts have issued 12-month price targets for Oxford Immunotec Global's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

News articles about OXFD stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Oxford Immunotec Global.

Oxford Immunotec Global saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 386,200 shares, a decline of 6.0% from the January 15th total of 411,000 shares. Based on an average daily trading volume, of 116,200 shares, the days-to-cover ratio is presently 3.3 days. Approximately 1.5% of the shares of the company are sold short. View Oxford Immunotec Global's Current Options Chain.

Some companies that are related to Oxford Immunotec Global include Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include AbbVie (ABBV), Immunomedics (IMMU), Intel (INTC), Sangamo Therapeutics (SGMO), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Gilead Sciences (GILD), Halozyme Therapeutics (HALO) and Centurylink (CTL).

Oxford Immunotec Global's stock is owned by many different of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (4.91%), Penn Capital Management Co. Inc. (2.91%), Senvest Management LLC (2.64%), Renaissance Technologies LLC (1.57%), Man Group plc (1.37%) and New York State Common Retirement Fund (1.27%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

OXFD stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Man Group plc, Oxford Asset Management LLP, Renaissance Technologies LLC, Oppenheimer & Co. Inc., Goldman Sachs Group Inc. and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

OXFD stock was purchased by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., New York State Common Retirement Fund, Knights of Columbus Asset Advisors LLC, Acadian Asset Management LLC, Senvest Management LLC, Alliancebernstein L.P., California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Oxford Immunotec Global.

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OXFD stock can currently be purchased for approximately $14.12.

Oxford Immunotec Global has a market capitalization of $373.47 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]